Hello, Welcome to Shine Consultant !
Summit & Event Shine Speaker Bureau Shine Advisor Shine Event Service
  • Summit & Event :
    With field research of markets and industries which is analyzed from a global strategic perspective by our professional teams, as well as hot topics which interest leadership and management, Shine Consultant provides you with one-stop platform of dialogue, practice -sharing and social network!
  • Shine Speaker Bureau:
    Committed to provide keynote speakers, executive learning masterclasses and boardroom advisory for global enterprises and institutions, each service provides a deeper and more interactive experience, especially for small, selected audiences and key individuals. We have the resources of the most influential business leaders and experts, who are the most outstanding representatives in their fields. Our team consists of experienced speech and event managers, and we focus on building long-term and in-depth partnerships.
  • Shine Advisor:
    As world-class insight network, we connects clients-decision makers with vetted subject matter experts-advisors. Our clients leverage the insights and perspectives shared by our advisors to stay informed and make better business decisions.We have over 600,000 Shine Advisors in 20 industries, which continues to grow every day.
  • Shine Event Service:
    Committed to be the world's most professional provider of industrial Summit & Event. We provide one-stop professional services, including investigating and planning, on-demand inviting, marketing and promoting, operating, project management, live& digital conference, each service is performed by an experienced professional team matched with long-term industrial resources. We focus on establishing long-term and in-depth partnerships.
Guest Information
发布时间: 2017 - 12 - 18
点击次数: 0
Positions: President
Company: 启德医药科技(苏州)有限公司
个人简介:
Dr. Gang Qin has more than 16 years of R&D and managing experiences in biomedical research. He obtained his PhD degree in 2005 at the European Neuroscience Institute Goettingen, Germany. Then he joined Max-Planck Institute of Biochemistry at Munich focusing on mechanistic characterization of protein degradation regulated cell proliferation. Thereafter, he moved back China and led one team at National Laboratory for Industrial Enzyme Engineering, CAS, there Dr. Qin dedicated himself to the field of enzyme engineering and chemical biology. At 2013 Dr. Qin founded GeneQuantum Healthcare (Suzhou ) Co. Ltd, currently he is the president. Dr. Qin has published series of high citation paper in international peer reviewed Journals including Journal of Neuroscience、 Nature Neuroscience、 Neuron etc., he is also major inventor of multiple PCT patents. GeneQuantum’s innovative Ligase Dependent Conjugation (LDC) technology, combined with IP protected Automatic On-line Monitoring Conjugation System and Linker Screening& Optimization Facility, provide a holistic solution for the R&D of next generation ADCs. GeneQuantum are focusing on developing series of next generation anti-tumor Antibody-Drug-Conjugates (ADCs) with best-in-class or first-in-class potential fulfilling the unmet clinical need.
发布时间: 2017 - 12 - 08
点击次数: 0
Positions: CEO
Company: Fosun Kite Biotechnology Co., Ltd
个人简介:
Richard Wang, Ph. D and MBA, Chief Executive Officer, Fosun Kite Biotechnology Co. Ltd (a joint venture between Fosun Pharma and Kite Pharma), since March, 2017. Prior to joining Fosun Kite, Richard was a Chief Operation Officer for the Cellular Biomedicine Group (NASDAQ: CBMG). Richard led CBMG day-to-day operations and provided leadership and oversight to multiple functions (e.g., preclinical pharmacology, clinical development, manufacturing and technology (CMC), regulatory, quality assurance, project and administration), and was specifically responsible for the company’s stem cell technology platform and therapeutic business unit. He also supported the company’s immunotherapy pipeline (CAR-T and therapeutic vaccine) from the aspects of manufacturing, clinical development and registration strategy. Before that, Richard functioned as a site leader, senior director and head of operations for the GSK R&D Center in China, a director of strategic alliance, portfolio and operations for the AstraZeneca Innovation Center China, an associate director of discovery and early development project management in Bristol-Myers Squibb US, and a discovery group leader and senior scientist of the Procter & Gamble Pharmaceutical in the US, for more than 20 years with increasing leadership responsibilities in the therapeutic areas of oncology, neuroscience, muscular-skeletal and inflammatory diseases.
发布时间: 2017 - 12 - 08
点击次数: 0
Positions: Vice President
Company: Tasly Holding Group
个人简介:
Dr. Sun is the Vice President at Tasly Group, and the CEO of Tasly Pharmaceuticals, Inc. of USA. Since joined Tasly in 2006, he has been focusing on innovative drug developments, research activity managements, and international R&D collaborations. Dr. Sun created several new drug innovation management models, such as the “reverse discovery” model, “labeling first” process, and “integrative development” SOP and thus far has led his team obtained 22 NDA approvals from 32 countries, established 7 international R&D Joint Ventures, and achieved 28 worldwide business deals worth $2 billion with those very top pharmaceuticals firms such as Transgene (France), Pharnext (France), Bayer (German). The most significant R&D activity of Dr. Sun is that he completed the historically worldwide first and only global phase III clinical development of a multi-herbal drug products under the US FDA regulations aimed for an NDA approval next year, which will generate significant interest in the biomedical space, and paves a new route for pharmaceutical R&D for complicated unmet medical needs. Dr. Sun is also serving as a full professor at Tianjin University of China, and Special Professor at University of Nottingham of UK, and Deputy Director at Center for TCM Research of Columbia University of NY, with 100+ publications in peer-reviewed medical and pharmaceutical journals.
发布时间: 2017 - 12 - 08
点击次数: 0
Positions: Venture Partner
Company: Lilly Asia Fund
个人简介:
Dr. Yining Zhao is currently a Venture Partner at Lilly Asia Ventures (LAV) responsible for cross-board investment between US and China. He has co-founded and become CEO for several US-China biotech companies such as Just Biotherapeutics, Veritas Genetics, and NuBiyota China Inc. etc, which are focused on precision medicine.  Prior to his entrepreneurial career, Dr. Zhao has worked in the areas of Strategy Management and Business Development at multinational biopharmaceutical companies for 20 years. He was Executive Strategy Director at Global Commercial Operations of Amgen based in Thousand Oaks, California. Before that he was the Asia Strategy Lead at Pfizer based in New York.Dr. Zhao received his B.S. in Pharmaceutical Sciences from Fudan University (Shanghai, China), Ph.D. in Analytical Chemistry from Ghent University (Ghent, Belgium), and MBA from Massachusetts Institute of Technology (Cambridge, USA). He has contributed more than 30 peer-reviewed publications and book chapters.
74页次12/19首页Previous...  78910111213141516...Next尾页